Elutia Inc. (NASDAQ:ELUT – Get Free Report) saw a significant growth in short interest in the month of June. As of June 30th, there was short interest totaling 52,925 shares, a growth of 106.2% from the June 15th total of 25,665 shares. Based on an average daily volume of 82,561 shares, the days-to-cover ratio is presently 0.6 days. Currently, 0.2% of the shares of the company are short sold.
Elutia Trading Up 4.1%
ELUT stock traded up $0.04 during trading on Wednesday, hitting $0.95. The company had a trading volume of 13,111 shares, compared to its average volume of 161,928. The firm has a market capitalization of $40.60 million, a price-to-earnings ratio of 1.10 and a beta of 0.85. The business has a 50 day moving average of $1.02 and a 200 day moving average of $1.01. Elutia has a fifty-two week low of $0.50 and a fifty-two week high of $2.50.
Elutia (NASDAQ:ELUT – Get Free Report) last announced its earnings results on Thursday, May 14th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). The company had revenue of $3.11 million for the quarter, compared to analysts’ expectations of $3.00 million.
Institutional Investors Weigh In On Elutia
Wall Street Analysts Forecast Growth
Several equities analysts have recently issued reports on ELUT shares. Weiss Ratings upgraded Elutia from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, July 7th. Wall Street Zen upgraded Elutia from a “sell” rating to a “hold” rating in a research report on Sunday, March 22nd. One research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $6.00.
View Our Latest Stock Report on Elutia
About Elutia
Elutia, Inc is a biopharmaceutical company focused on the development of novel nitric oxide therapies based on its proprietary polymeric nitric oxide platform. This technology is designed to enable sustained, controlled release of nitric oxide to targeted tissues, potentially overcoming the delivery challenges associated with gaseous nitric oxide and small‐molecule donors.
The company’s lead program is in preclinical development for pulmonary arterial hypertension, with additional research efforts aimed at other cardiovascular and respiratory conditions.
Featured Stories
- Five stocks we like better than Elutia
- Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity
- CPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive Stocks
- Why ASML’s AI Monopoly Is Still Getting Stronger
- Apple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before Earnings
Receive News & Ratings for Elutia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elutia and related companies with MarketBeat.com's FREE daily email newsletter.
